# ProtoKinetix, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/ProtoKinetix, Inc.). ## Overview ProtoKinetix, Inc. is a U.S.-based biotechnology company focused on research and development of AFGPs, or anti-freeze glycoproteins, marketed under the AAGP® trademark. The company’s work centers on advancing this molecule toward commercial use in targeted healthcare and other medical applications, with research, validation, and partnering activities as core parts of the business. ## Products & services • AAGP® anti-aging glycoprotein research and development • AFGP-based scientific and medical validation • Molecule storage and related research support • Intellectual property development around AAGP® • Commercial partnering for healthcare applications - **AAGP® research and development** (70%) — Scientific work to validate and advance the AAGP® molecule for medical use. - **Commercialization and partnering** (20%) — Activities to secure collaborators and commercial entities for market entry. - **Intellectual property and patent activity** (10%) — Patent-related work and protection of the AAGP® technology platform. - AAGP® anti-aging glycoprotein research and development - AFGP-based scientific and medical validation - Molecule storage and related research support - Intellectual property development around AAGP® - Commercial partnering for healthcare applications ## Customers ProtoKinetix does not appear to sell a broad commercial product set today; instead, its counterparties are mainly researchers, advisors, business partners, and potential commercial entities involved in validating AAGP®. If the technology is commercialized, the end customers would likely be healthcare organizations and other users of targeted medical solutions. The company’s current “customers” are therefore more partnership-oriented than traditional product buyers. - **Research collaborators** (primary) — Universities, labs, and scientific partners that help test and validate AAGP®. - **Commercial partners** (primary) — Business entities that may help fund, license, or commercialize AAGP®. - **Healthcare solution end users** (emerging) — Future buyers of targeted health care applications built on AAGP®. - **Grant and institute partners** (secondary) — Institutions that may support continued studies through grants or programs. - Research collaborators helping validate AAGP® applications - Business advisors and commercial partners supporting market entry - Potential healthcare customers for targeted medical solutions - Institutes and grant-linked research partners - Consultants and service providers supporting development ## Geography ProtoKinetix is headquartered in the United States and reports U.S. GAAP financial statements. The filings also reference Canada in the context of tax exposure, suggesting some cross-border business or planning considerations, but the company’s operating footprint appears centered in North America. Geography matters mainly through research collaboration, tax treatment, and the location of future commercialization partners rather than through a broad manufacturing network. - Headquartered in the United States - Cross-border tax exposure referenced for the U.S. and Canada - North American focus for research and commercialization efforts - No disclosed country revenue split in the excerpts - Geography is driven by partners and research activity, not manufacturing ## Strategy The company’s strategy is to move AAGP® from scientific research toward practical commercial validation and eventual market use. It is also seeking research partners, grant-supported institutes, and commercial entities to share development costs and improve the path to commercialization. - **Commercial validation of AAGP®** (short-term) — The molecule must be validated before it can support meaningful commercialization. - **Partnering and cost sharing** (short-term) — External partners can reduce funding needs and accelerate development. - **AAGP® commercialization** (medium-term) — Longer-term value depends on turning the molecule into marketable applications. - Advance AAGP® from lab research to commercial validation - Build partnerships to share research and development costs - Pursue grant-supported institutes for continued studies - Develop commercialization pathways for healthcare applications - Protect and expand the AAGP® intellectual property position ## Risks ProtoKinetix faces the typical risks of an early-stage biotechnology company: uncertain scientific outcomes, dependence on external funding, and a long path from research to commercialization. Company-specific risks also include retaining key scientific consultants, protecting intellectual property, and managing common stock volatility while funding operations through equity issuance. - **Going concern and funding dependence** [critical] — The company has limited cash and relies on external financing to continue operations. - **Scientific and development failure** [high] — AAGP® may not achieve the validation needed for commercial use. - **Dilution from common stock issuance** [high] — The company intends to fund itself by selling common stock. - **Retention of key scientific consultants** [medium] — The business depends on specialized expertise to advance research. - **Competition and intellectual property** [medium] — Competing technologies or weak IP protection could limit adoption. - Scientific and commercialization success is uncertain - Funding depends heavily on equity issuance and investor support - Key management and scientific consultant retention is critical - IP protection is central to the AAGP® value proposition - Common stock volatility can affect financing capacity ## Accounting ProtoKinetix’s accounting is shaped by an early-stage R&D model with limited or no product revenue, so expenses and capitalized development-related items are especially important. Investors should watch estimates around share-based compensation, patent-related costs, and going-concern disclosures, since these can materially affect reported losses and the interpretation of liquidity. - **Share-based compensation valuation** — Can materially affect operating expenses and equity - **Patent and development-related spending** — Affects investing cash flow and period expenses - **Going-concern assessment** — Important for liquidity interpretation and disclosure - **Estimates and assumptions** — Can change reported expenses and financial condition - No product revenue means expenses drive reported results - Share-based compensation uses Black-Scholes valuation - Patent application and related costs affect investing cash flow - Going-concern disclosure reflects liquidity assumptions - Estimates and assumptions can materially change reported losses --- *Last updated: 2026-04-29T04:49:57.639665+00:00*